Clinical trial
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
NCT02466971 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- May 10, 2016
- Completion date
- July 14, 2027
- Enrollment
- 450 (actual)
- Sites
- 381
Conditions
As the registry lists them; a condition with its own page is linked.
advanced vaginal adenocarcinoma, advanced vaginal adenosquamous carcinoma, advanced vaginal squamous cell carcinoma, cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical squamous cell carcinoma, stage ib2 cervical cancer ajcc v6 and v7, stage ii cervical cancer ajcc v7, stage ii vaginal cancer ajcc v6 and v7, stage iia cervical cancer ajcc v7, stage iib cervical cancer ajcc v6 and v7, stage iii vaginal cancer ajcc v6 and v7, stage iiib cervical cancer ajcc v6 and v7, stage iv vaginal cancer ajcc v6 and v7, stage iva cervical cancer ajcc v6 and v7, stage iva vaginal cancer ajcc v6 and v7, unresectable vaginal carcinoma, vaginal adenocarcinoma, vaginal adenosquamous carcinoma, vaginal carcinoma, vaginal squamous cell carcinoma, not otherwise specified